Literature DB >> 26604151

Gene therapy for lysosomal storage disorders: a good start.

Alessandra Biffi1.   

Abstract

Lysosomal storage disorders (LSDs) are a heterogeneous group of inherited diseases with a collective frequency of ∼1 in 7000 births, resulting from the deficiency in one or more enzymes or transporters that normally reside within the lysosomes. Pathology results from the progressive accumulation of uncleaved lipids, glycoproteins and/or glycosaminoglycans in the lysosomes and secondary damages that affect the brain, viscera, bones and connective tissues. Most treatment modalities developed for LSD, including gene therapy (GT), are based on the lysosome-specific cross-correction mechanism, by which close proximity of normal cells leads to the correction of the biochemical consequences of enzymatic deficiency within the neighboring cells. Here, GT efforts addressing these disorders are reviewed with an up-to-date discussion of their impact on the LSD disease phenotype in animal models and patients.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2015        PMID: 26604151     DOI: 10.1093/hmg/ddv457

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  15 in total

Review 1.  Emptying the stores: lysosomal diseases and therapeutic strategies.

Authors:  Frances M Platt
Journal:  Nat Rev Drug Discov       Date:  2017-11-17       Impact factor: 84.694

Review 2.  Impact of lysosome status on extracellular vesicle content and release.

Authors:  Erez Eitan; Caitlin Suire; Shi Zhang; Mark P Mattson
Journal:  Ageing Res Rev       Date:  2016-05-26       Impact factor: 10.895

3.  Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease.

Authors:  Sophia-Martha Kleine Holthaus; Mikel Aristorena; Ryea Maswood; Olha Semenyuk; Justin Hoke; Aura Hare; Alexander J Smith; Sara E Mole; Robin R Ali
Journal:  Hum Gene Ther       Date:  2020-07       Impact factor: 5.695

4.  Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA.

Authors:  Andrés Felipe Leal; Carlos Javier Alméciga-Díaz
Journal:  Gene Ther       Date:  2022-05-18       Impact factor: 5.250

Review 5.  Dosage Compensation in Females with X-Linked Metabolic Disorders.

Authors:  Patrycja Juchniewicz; Ewa Piotrowska; Anna Kloska; Magdalena Podlacha; Jagoda Mantej; Grzegorz Węgrzyn; Stefan Tukaj; Joanna Jakóbkiewicz-Banecka
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 6.  Glial Dysfunction and Its Contribution to the Pathogenesis of the Neuronal Ceroid Lipofuscinoses.

Authors:  Keigo Takahashi; Hemanth R Nelvagal; Jenny Lange; Jonathan D Cooper
Journal:  Front Neurol       Date:  2022-04-04       Impact factor: 4.086

Review 7.  Biomarkers in Lysosomal Storage Diseases.

Authors:  Joaquin Bobillo Lobato; Maria Jiménez Hidalgo; Luis M Jiménez Jiménez
Journal:  Diseases       Date:  2016-12-17

8.  Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.

Authors:  Marialuisa Alliegro; Rita Ferla; Edoardo Nusco; Chiara De Leonibus; Carmine Settembre; Alberto Auricchio
Journal:  Mol Ther       Date:  2016-09-23       Impact factor: 11.454

9.  Cryo-EM structures of the human endolysosomal TRPML3 channel in three distinct states.

Authors:  Xiaoyuan Zhou; Minghui Li; Deyuan Su; Qi Jia; Huan Li; Xueming Li; Jian Yang
Journal:  Nat Struct Mol Biol       Date:  2017-11-06       Impact factor: 15.369

10.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.